Lázaro-Muñoz, G
Farrell, M S
Crowley, J J
Filmyer, D M
Shaughnessy, R A
Josiassen, R C
Sullivan, P F
Article History
Received: 21 June 2017
Revised: 27 September 2017
Accepted: 2 October 2017
First Online: 21 November 2017
Competing interests
: PF Sullivan reports the following potentially competing financial interests: Element Genomics (Scientific Advisory Board member, stock options), Lundbeck (advisory committee), Pfizer (Scientific Advisory Board member) and Roche (grant recipient, speaker reimbursement). The other authors declare no conflicts of interest.